|
|
|
 Emerging
DES |
| Examination of anti-intima hyperplastic
effect on Cilostazol eluting stent in porcine model |
| By Dr. Etsuo Tsuchikane |
The problem of restenosis
has led to develop the drug-eluting stents (DESs).
Some of them have already demonstrated promising
results in terms of reducing the restenosis.
However, current cytotoxic DESs delay the endothelialization
and/or induce stent malapposition due to the termination
of cell cycle. Cilostazol, C-AMP phosphodiesterase
inhibitor, is anti-platelet agent that possesses
the anti-intima hyperplastic property and is known
to accelerate endothelialization. Post stent oral
administration of cilostazol demonstrated preventing
the restenosis. In the current study Dr. Tsuchikane
and his colleagues aimed at examining the effectiveness
of Cilostazol eluting stent (CES) in porcine model.
Either stent coated with 400 ?g Cilostazol around
the bio-absorbable polymer or bare metal stent (BMS)
was implanted in twelve porcinis (CESs 12 and BMSs
12) in double blind manner. The porcinis were sacrificed
after 28 days to remove and embed their coronary
arteries. The initial result on late loss demonstrated
a significant difference between the groups (1.86?1.04
vs. 0.82?0.81, BMS and CES respectively). They also
found the results of pathologic sectioned arterial
tissues observed in each area of neo-intima and
lumen. Regarding the injury and inflammation score,
no significant difference was observed in each group.
However this pathological result demonstrated significant
differences on intima and lumen area between the
groups (intima area: BMS 2.05?0.82 vs. CES 1.58?0.80;
p=0.04 lumen area: BMS 2.49?1.57 vs. CES 3.59?1.54;
p=0.01).
These results warrant further studies to assess
the efficacy of Cilostazol eluting stent. |
|
|
|
|
|
